Activin and Inhibin

Adenosine receptor antagonist 2 is an orally active A2a/A2b adenosine receptor antagonist with IC 50 s of 1 nM and 3 nM, respectively. Adenosine receptor antagonist 2 has anti-tumor activityIn VivoAdenosine receptor antagonist 2 (compound L-1: po:

Adenosine receptor antagonist 2 is an orally active A2a/A2b adenosine receptor antagonist with IC 50 s of 1 nM and 3 nM, respectively. Adenosine receptor antagonist 2 has anti-tumor activityIn VivoAdenosine receptor antagonist 2 (compound L-1: po:

Adenosine receptor antagonist 3 is a potent antagonist of adenosine receptor. Adenosine receptor antagonist 3 has the potential for the research of cancer disease (extracted from patent WO2019233994A1, compound 1).Form:Solid.

Adenosine receptor antagonist 3 is a potent antagonist of adenosine receptor. Adenosine receptor antagonist 3 has the potential for the research of cancer disease (extracted from patent WO2019233994A1, compound 1).Form:Solid.

Adenosine receptor antagonist 3 is a potent antagonist of adenosine receptor. Adenosine receptor antagonist 3 has the potential for the research of cancer disease (extracted from patent WO2019233994A1, compound 1).Form:Solid.

Adenosine receptor antagonist 3 is a potent antagonist of adenosine receptor. Adenosine receptor antagonist 3 has the potential for the research of cancer disease (extracted from patent WO2019233994A1, compound 1).Form:Solid.

Adenosine receptor antagonist 3 is a potent antagonist of adenosine receptor. Adenosine receptor antagonist 3 has the potential for the research of cancer disease (extracted from patent WO2019233994A1, compound 1).

ADRA1D receptor antagonist 1 is a potent, selective and orally active α 1D adrenoceptor antagonist, with a K i of 1.6 nMIn VitroADRA1D receptor antagonist 1 shows low hERG inhibition. ADRA1D receptor antagonist 1 exhibits higher selectivity for

ADRA1D receptor antagonist 1 is a potent, selective and orally active α 1D adrenoceptor antagonist, with a K i of 1.6 nMIn VitroADRA1D receptor antagonist 1 shows low hERG inhibition. ADRA1D receptor antagonist 1 exhibits higher selectivity for

ADRA1D receptor antagonist 1 is a potent, selective and orally active α 1D adrenoceptor antagonist, with a K i of 1.6 nMIn VitroADRA1D receptor antagonist 1 shows low hERG inhibition. ADRA1D receptor antagonist 1 exhibits higher selectivity for

Adrenocorticotropic Hormone (ACTH) (1-39), human(TFA) is a melanocortin receptor agonist.Appearance:SolidIC50&amp: Target:Melanocortin receptorIn Vitro:Adrenocorticotropic Hormone (ACTH) (1-39), human (ACTH 1-39), a member of the melanocortin

Adrenocorticotropic Hormone (ACTH) (1-39), human(TFA) is a melanocortin receptor agonist.Appearance:SolidIC50&amp: Target:Melanocortin receptorIn Vitro:Adrenocorticotropic Hormone (ACTH) (1-39), human (ACTH 1-39), a member of the melanocortin